https://www.selleckchem.com/pr....oducts/resiquimod.ht
rrhea [n = 52], vomiting [n = 28], and rash [n = 31]) and patients in the placebo group had 640 adverse events (nausea [n = 67], diarrhea [n = 84], vomiting [n = 20], and rash [n = 20]). Among patients with moderate or severe IPF, treatment with oral co-trimoxazole did not reduce a composite outcome of time to death, transplant, or nonelective hospitalization compared with placebo. ISRCTN Identifier ISRCTN17464641. ISRCTN Identifier ISRCTN17464641.A vast proportion of coronavirus disease 2019 (COVID-19) individuals remain asymptomati
Like
Comment
Share
